Your Article Summary
See Latest ArticlesPhase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95
Journal of Clinical Oncology, 06/22/09
Wiegel T et al. - Adjuvant radiotherapy (RT) for pT3 prostate cancer with postoperatively undetectable PSA significantly reduces the risk of biochemical progression. Further follow-up is needed to assess the effect on metastases-free and overall survival.
Methods- Study to compare radical prostatectomy (RP) followed by immediate RT for pts with pT3 PCa and an undetectable PSA after RP
- Eligible pts had pT3 pN0 tumors; after RP:
- 192 men were randomly assigned to a wait-and-see policy, and
- 193 men were assigned to immediate postoperative RT
- Pts who did not achieve an undetectable PSA after RP were excluded
- Of the remaining 307 pts, 34 pts on the RT arm did not receive RT and 5 pts on the wait-and-see arm received RT
- Therefore, 114 pts underwent RT and 154 pts were treated with a wait-and-see policy
- The primary end point: biochemical progression-free survival (PFS)
- Biochemical PFS after 5 yrs in pts with undetectable PSA after RP was significantly improved in the RT group
- Univariate analysis: Gleason score >6 and <7, PSA before RP, tumor stage, and positive surgical margins were predictors of outcome
- Rate of grade 3 to 4 late adverse effects was 0.3%
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?
Annals of Oncology, 11/17/09
Ovarian cancer screening and early detection
Women's Health, 11/04/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09